


N30 PHARMACEUTICALS

The leader in developing new s-nitrosoglutathione (SNO)-based drugs

N30 Pharma's drugs target s-nitrosoglutathione reductase (GSNOR), an enzyme of central importance in human health and disease.

These drugs inhibit GSNOR, the most selective enzyme that breaks down s-nitrosoglutathione (GSNO), a key component of the human body's pool of bioavailable nitric oxide. GSNO and SNOs are important modulators of inflammation, cell death, organ regeneration, and respiratory, vascular, and gastrointestinal function.



Dimeric Structure of GSNOR

Inhibition of GSNOR increases the levels of endogenous, bioreactive nitric oxide. Modulating GSNOR enzymatic activity is an important new therapeutic strategy for the treatment of major diseases such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease, and vascular disease.

Highlights of N30 Pharma Development:

N30 Pharma has developed a platform of chemistry, biology, advanced analytic techniques, and state-of-the-art clinical testing. This has resulted in a broad portfolio of high potency (nM) compounds within multiple chemotypes.


N30 Pharma drug candidates have demonstrated efficacy in a broad range of human disease models. These drugs are notable in their broad anti-inflammatory activity, effect on smooth muscle, duration of effect, safety profile, and varying methods of administration, including I.V., oral, and inhalation.




N30 PHARMACEUTICALS

The leader in developing new s-nitrosoglutathione (SNO)-based drugs

These drugs are protected by a patent portfolio built upon compositional claims. N30 Pharma's first drug candidate N6022, initially targeting respiratory disease, is now in human testing.



N30 Pharma GSNOR Inhibitors Inflammation and Airspace Enlargement in Experimental COPD



N30 Pharma GSNOR Inhibitors Preserve GI Integrity Experimental Inflammatory Bowel Disease

Executive Management:

Charles Scoggin, M.D.: Chief Executive Officer

Gary Rosenthal, PhD: Executive Vice President Research

Janice Troha, VP Development and Regulatory

Tom Sokolowski, CFO and VP Finance

N30 PHARMACEUTICALS

The leader in developing new s-nitrosoglutathione (SNO)-based drugs

Scientific Advisors:

Joseph Loscalzo, M.D., PhD: Harvard Medical School
Augustine Choi, M.D.: Harvard Medical School
Michael Marletta, PhD: University of California, Berkeley
Joseph Vita, M.D.: Boston University
William Sessa, PhD: Yale
Jan Wasley, PhD: Simpharma

Board of Directors:

Arnold Snider: Chairman
Joseph Loscalzo, M.D., PhD: Harvard Medical School
Howard Furst, M.D.: Deerfield Management
Michael Treisman: Tiger Management
Charles Scoggin, M.D.: CEO, N30 Pharma

Investors:

Tiger Management
Deerfield Management
Arnold Snider
Bridger Capital
Swift Current Partners
Duke University

N30 Pharmaceuticals, LLC:

3122 Sterling Circle, Suite 200
Boulder, Colorado 80301
V: 720.945.7700
F: 303.440.8399
Web: www.n30pharma.com

